These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 28240046)

  • 21. [Pharmacokinetics, interactions and mechanism of action of maraviroc].
    Soriano V; Poveda E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():12-6. PubMed ID: 19133216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early events of HIV-1 infection: can signaling be the next therapeutic target?
    Jones KL; Smyth RP; Pereira CF; Cameron PU; Lewin SR; Jaworowski A; Mak J
    J Neuroimmune Pharmacol; 2011 Jun; 6(2):269-83. PubMed ID: 21373988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of HIV-1 entry into cells.
    Copeland KF
    Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):107-12. PubMed ID: 18221139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Past, present, and future of entry inhibitors as HIV microbicides.
    Gibson RM; Arts EJ
    Curr HIV Res; 2012 Jan; 10(1):19-26. PubMed ID: 22264042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of HIV-1 entry: multiple keys to close the door.
    Hertje M; Zhou M; Dietrich U
    ChemMedChem; 2010 Nov; 5(11):1825-35. PubMed ID: 20845361
    [No Abstract]   [Full Text] [Related]  

  • 26. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.
    Sierra-Aragón S; Walter H
    Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanoscale drug delivery for targeted chemotherapy.
    Xin Y; Huang Q; Tang JQ; Hou XY; Zhang P; Zhang LZ; Jiang G
    Cancer Lett; 2016 Aug; 379(1):24-31. PubMed ID: 27235607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human respiratory viral infections: Current status and future prospects of nanotechnology-based approaches for prophylaxis and treatment.
    Dawre S; Maru S
    Life Sci; 2021 Aug; 278():119561. PubMed ID: 33915132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there a future for antiviral fusion inhibitors?
    Berkhout B; Eggink D; Sanders RW
    Curr Opin Virol; 2012 Feb; 2(1):50-9. PubMed ID: 22440966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitors of HIV-1 entry and integration: recent developments and impact on treatment.
    Sharma AK; George V; Valiathan R; Pilakka-Kanthikeel S; Pallikkuth S
    Recent Pat Inflamm Allergy Drug Discov; 2013 May; 7(2):151-61. PubMed ID: 23578097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fusion Stage of HIV-1 Entry Depends on Virus-Induced Cell Surface Exposure of Phosphatidylserine.
    Zaitseva E; Zaitsev E; Melikov K; Arakelyan A; Marin M; Villasmil R; Margolis LB; Melikyan GB; Chernomordik LV
    Cell Host Microbe; 2017 Jul; 22(1):99-110.e7. PubMed ID: 28704658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanomicrobicides for HIV vaginal transmission prevention: where do we stand?
    Agrahari V
    Ther Deliv; 2017 Jul; 8(8):601-606. PubMed ID: 28730940
    [No Abstract]   [Full Text] [Related]  

  • 34. High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.
    Marin M; Du Y; Giroud C; Kim JH; Qui M; Fu H; Melikyan GB
    Assay Drug Dev Technol; 2015 Apr; 13(3):155-66. PubMed ID: 25871547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New kinds of AIDS drugs inhibit HIV entry into the cell. Entry inhibitors soon for oral administration].
    Fätkenheuer G
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():46-8. PubMed ID: 16385874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Updating the use of synthetic peptides as inhibitors of HIV-1 entry.
    Gómara MJ; Haro I
    Curr Med Chem; 2014 Apr; 21(10):1188-200. PubMed ID: 23931277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted therapeutics--from chemical structures to diagnostic and therapeutic agents.
    Armbruster C
    Curr Pharm Des; 2009; 15(2):118-9. PubMed ID: 19149607
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor.
    Vermeire K; Schols D
    Expert Opin Investig Drugs; 2005 Oct; 14(10):1199-212. PubMed ID: 16185162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic targeting of interactions between Nef and host cell proteins.
    Saksela K
    Curr Drug Targets Immune Endocr Metabol Disord; 2004 Dec; 4(4):315-9. PubMed ID: 15578982
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.